AnaptysBio has abandoned plans to develop rosnilimab for ulcerative colitis (UC) after the PD-1 agonist flunked a phase 2 study. The San Diego-based biopharma assessed rosnilimab in the midstage study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results